During the past two decades invasive fungal infections have emerged as major causes of
morbidity and mortality in immunocompromised patients. Several factors have contributed to …

The past few years have seen the advent of several new antifungal agents, including those
of a new class and a new generation of an existing class. Caspofungin, the first available …

Traditionally, many invasive fungal infections were associated with a poor prognosis,
because effective therapeutic options were limited. The recent development of new …

During the past two decades the frequencies and types of life-threatening fungal infections
have increased dramatically in immunocompromised patients (7, 220, 232, 282). Several …

As invasive fungal infections in immunocompromised patients become increasingly
important, the field of antifungal chemotherapy continues to evolve rapidly. New agents have …

Topical antifungal agents are generally used for the treatment of superficial fungal infections
unless the infection is widespread, involves an extensive area, or is resistant to initial …

Invasive, life-threatening fungal infections are an important cause of morbidity and mortality,
particularly for patients with compromised immune function. The number of therapeutic …

Continued advancement of medical science offers life-saving treatment options for a variety
of hematologic, oncologic, and rheumatologic conditions. Immunosuppression, a common …

Infections caused by yeasts and molds continue to be associated with high rates of morbidity
and mortality in both immunocompromised and immunocompetent patients. Many antifungal …

The number of agents available to treat fungal infections has increased by 30% since the
year 2000, yet still only 15 agents are currently approved for clinical use. The greater …